Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shi-Yong Sun

Showing results (11-20 of 206) with videos related to

Pageof 21
Sort By:
Translational Oncology|August 28, 2020
Searching for the real function of mTOR signaling in the regulation of PD-L1 expressionShi-Yong Sun
Frontiers of Medicine|November 9, 2020
mTOR-targeted cancer therapy: great target but disappointing clinical outcomes, why?Shi-Yong Sun
Cancer Letters|September 5, 2024
Is tumor microenvironment important for targeted therapy in lung cancer?Shi-Yong Sun
Expert Opinion on Therapeutic Targets|August 22, 2009
Enhancing mTOR-targeted cancer therapyXuerong Wang, Shi-Yong Sun
Oncoscience|January 17, 2015
c-FLIP links mTORC2 to apoptosisLiqun Zhao, Shi-Yong Sun
Frontiers in Oncology|August 12, 2022
Editorial: Challenges and opportunities of TKIs in the treatment of NSCLC patients with uncommon mutationsChunxia Su, Shi-Yong Sun
Oncoscience|August 9, 2021
Re-enforcing the strategy of targeting MEK/ERK signaling to overcome acquired resistance to third generation EGFR inhibitorsWen Zhao, Shi-Yong Sun
Critical Reviews in Oncology/Hematology|February 14, 2002
Retinoids and their receptors in cancer development and chemopreventionShi-Yong Sun, Reuben Lotan
Oncoscience|September 20, 2021
Taking action early to manage emergence of acquired resistance to osimertinib or other third generation EGFR inhibitorsGuangzhi Ma, Shi-Yong Sun
Translational Cancer Research|September 12, 2024
Fourth-generation epidermal growth factor receptor-tyrosine kinases inhibitors: hope and challengesChunxia Su, Shi-Yong Sun
Pageof 21

Showing results (11-20 of 206) with videos related to

Sort By:
Pageof 21
Translational Oncology|August 28, 2020
Searching for the real function of mTOR signaling in the regulation of PD-L1 expressionShi-Yong Sun
Frontiers of Medicine|November 9, 2020
mTOR-targeted cancer therapy: great target but disappointing clinical outcomes, why?Shi-Yong Sun
Cancer Letters|September 5, 2024
Is tumor microenvironment important for targeted therapy in lung cancer?Shi-Yong Sun
Expert Opinion on Therapeutic Targets|August 22, 2009
Enhancing mTOR-targeted cancer therapyXuerong Wang, Shi-Yong Sun
Oncoscience|January 17, 2015
c-FLIP links mTORC2 to apoptosisLiqun Zhao, Shi-Yong Sun
Frontiers in Oncology|August 12, 2022
Editorial: Challenges and opportunities of TKIs in the treatment of NSCLC patients with uncommon mutationsChunxia Su, Shi-Yong Sun
Oncoscience|August 9, 2021
Re-enforcing the strategy of targeting MEK/ERK signaling to overcome acquired resistance to third generation EGFR inhibitorsWen Zhao, Shi-Yong Sun
Critical Reviews in Oncology/Hematology|February 14, 2002
Retinoids and their receptors in cancer development and chemopreventionShi-Yong Sun, Reuben Lotan
Oncoscience|September 20, 2021
Taking action early to manage emergence of acquired resistance to osimertinib or other third generation EGFR inhibitorsGuangzhi Ma, Shi-Yong Sun
Translational Cancer Research|September 12, 2024
Fourth-generation epidermal growth factor receptor-tyrosine kinases inhibitors: hope and challengesChunxia Su, Shi-Yong Sun
Pageof 21